** Brokerage Guggenheim raises PT on drug developer Travere Therapeutics to $45 from $41
** New PT represents a 142% upside to the stock's Monday close
** TVTX's Filspari is an FDA-approved drug for the treatment of IgA nephropathy (IgAN), a type of disease where a protein called IgA builds up in the kidneys, causing inflammation
** On Monday, TVTX reported $50 mln in preliminary Filspari net product sales in 4Q 2024, which is "somewhat above investor expectations" of $45 mln, brokerage says
** Brokerage says it is "increasingly optimistic" about Filspari's potential in IgAN and its potential label expansion to Focal Segmental Glomerulosclerosis $(FSGS)$, a type of kidney disease, representing a $2 bln peak sales opportunity in the U.S.
** Brokerage forecasts annual U.S. Filspari sales for 2025 at $266 mln
** TVTX gained ~82 in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。